Ustering of endemic Burkitt’s lymphoma in highrisk regions of Kenya. Int J Cancer. 2007; 120:12127. [PubMed: 17019706] 24. Hjalgrim H, Rostgaard K, Johnson Pc, Lake A, Shield L, Small AM, EkstromSmedby K, Adami HO, Glimelius B, HamiltonDutoit S, et al. HLAA alleles and infectious mononucleosis recommend a essential role for cytotoxic Tcell response in EBVrelated Hodgkin lymphoma. Proc Natl Acad Sci U S A. 2010; 107:6400405. [PubMed: 20308568] 25. Sumaya CV, Myers LW, Ellison GW. EpsteinBarr virus antibodies in numerous sclerosis. Arch Neurol. 1980; 37:946. [PubMed: 6243930] 26. Munger KL, Levin LI, O’Reilly EJ, Falk KI, Ascherio A. AntiEpsteinBarr virus antibodies as serological markers of multiple sclerosis: a potential study amongst Usa military personnel. Mult Scler. 2011; 17:1185193. [PubMed: 21685232] 27. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV. An updated metaanalysis of threat of a number of sclerosis following infectious mononucleosis. PLoS A single. 2010:5. 28. Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, Gasperini C, Buttari F, Centonze D, et al. Enhanced CD8 T cell response to EpsteinBarr virus lytic antigens inside the active phase of multiple sclerosis.BuyPyrimidine-2-carbaldehyde PLoS Pathog. 2013; 9:e1003220. [PubMed: 23592979]NIHPA Author Manuscript NIHPA Author Manuscript NIHPA Author ManuscriptCurr Opin Virol. Author manuscript; accessible in PMC 2015 June 01.BalfourPage29. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, BarOr A, Panzara M, Sarkar N, Agarwal S, et al. Bcell depletion with rituximab in relapsingremitting several sclerosis. N Engl J Med. 2008; 358:67688. [PubMed: 18272891] 30. Cohen JI, Mocarski ES, RaabTraub N, Corey L, Nabel GJ.(1S)-(+)-(10-Camphorsulfonyl)oxaziridine Order The need to have and challenges for development of an EpsteinBarr virus vaccine. Vaccine. 2013; 31 (Suppl 2):B19496. [PubMed: 23598481] 31. Balfour HH Jr, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age particular prevalence of EpsteinBarr virus infection among men and women aged 69 years in the Usa and aspects affecting its acquisition. J Infect Dis. 2013; 208:1286293. [PubMed: 23868878]NIHPA Author Manuscript NIHPA Author Manuscript NIHPA Author ManuscriptCurr Opin Virol. Author manuscript; available in PMC 2015 June 01.BalfourPageHighlights Prophylactic and therapeutic EBV vaccines have already been tested but none is licensed. Best progress to date: prevention of infectious mononucleosis by a gp350 vaccine. Complications are lack of an animal model and acquiring the top immunogen and adjuvant. Prospects include things like prevention of mono, PTLD, MS, and therapy of EBVrelated cancer.NIHPA Author Manuscript NIHPA Author Manuscript NIHPA Author ManuscriptCurr Opin Virol.PMID:33557640 Author manuscript; out there in PMC 2015 June 01.TableBalfourProspects, progress, and difficulties in EBV vaccine developmentProgress Infectious mononucleosis was prevented in a phase two study using a subunit gp350 vaccine [7]. A CD8 Tcell peptide vaccine was immunogenic using a hint of efficacy [11]. A vaccinia construct expressing EBV membrane glycoprotein was immunogenic and may well have reduced incidence of EBV infection in Chinese children [3]. A subunit gp350 vaccine was protected in pediatric renal transplant candidates [8]. A vaccinia recombinant vector expressing the tumorassociated viral antigens EBNA1 and LMP2 was safe and immunogenic [12]. Proof that a vaccine could function: EBVspecific CD8 T cell responses are elevated throughout active MS [28]; monoclonal antibodies t.
